Literature DB >> 34045345

Bispecific antibodies.

Ulrich Brinkmann1, Roland E Kontermann2.   

Abstract

Year:  2021        PMID： 34045345     DOI： 10.1126/science.abg1209

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  9 in total

Review 1.  Insights into intercellular receptor-ligand binding kinetics in cell communication.

Authors:  Chenyi An; Xiaohuan Wang; Fan Song; Jinglei Hu; Long Li
Journal:  Front Bioeng Biotechnol       Date:  2022-06-28

2.  Grabbing the Bull by Both Horns: Bovine Ultralong CDR-H3 Paratopes Enable Engineering of 'Almost Natural' Common Light Chain Bispecific Antibodies Suitable For Effector Cell Redirection.

Authors:  Daniel Klewinghaus; Lukas Pekar; Paul Arras; Simon Krah; Bernhard Valldorf; Harald Kolmar; Stefan Zielonka
Journal:  Front Immunol       Date:  2022-01-11       Impact factor: 7.561

3.  Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer.

Authors:  Huicheng Liu; Lili Bai; Liu Huang; Na Ning; Lin Li; Yijia Li; Xuejiao Dong; Qiuyang Du; Minghui Xia; Yufei Chen; Likun Zhao; Yanhu Li; Qingwu Meng; Jing Wang; Yaqi Duan; Jie Ming; Andy Qingan Yuan; Xiang-Ping Yang
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

4.  Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.

Authors:  Nadine Aschmoneit; Lennart Kühl; Oliver Seifert; Roland E Kontermann
Journal:  J Immunother Cancer       Date:  2021-11       Impact factor: 13.751

5.  IgG-like Bispecific Antibody CD3×EpCAM Generated by Split Intein Against Colorectal Cancer.

Authors:  Lei Wang; Yu Qiao; Huifang Zong; Lei Han; Yong Ke; ZhiDi Pan; Jie Chen; Jun Lu; Jinyao Li; Tianlei Ying; Baohong Zhang; Jianwei Zhu
Journal:  Front Pharmacol       Date:  2022-02-23       Impact factor: 5.810

6.  A Hybrid Soluble gp130/Spike-Nanobody Fusion Protein Simultaneously Blocks Interleukin-6 trans-Signaling and Cellular Infection with SARS-CoV-2.

Authors:  Julia Ettich; Julia Werner; Hendrik T Weitz; Eva Mueller; Roland Schwarzer; Philipp A Lang; Jürgen Scheller; Jens M Moll
Journal:  J Virol       Date:  2021-12-22       Impact factor: 5.103

7.  The eIg technology to generate Ig-like bispecific antibodies.

Authors:  Lennart Kühl; Nadine Aschmoneit; Roland E Kontermann; Oliver Seifert
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

Review 8.  Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question.

Authors:  Camila Ordóñez-Reyes; Juan Esteban Garcia-Robledo; Diego F Chamorro; Andrés Mosquera; Liliana Sussmann; Alejandro Ruiz-Patiño; Oscar Arrieta; Lucia Zatarain-Barrón; Leonardo Rojas; Alessandro Russo; Diego de Miguel-Perez; Christian Rolfo; Andrés F Cardona
Journal:  Pharmaceutics       Date:  2022-06-11       Impact factor: 6.525

9.  An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics.

Authors:  Norbert Furtmann; Marion Schneider; Nadja Spindler; Bjoern Steinmann; Ziyu Li; Ingo Focken; Joachim Meyer; Dilyana Dimova; Katja Kroll; Wulf Dirk Leuschner; Audrey Debeaumont; Magali Mathieu; Christian Lange; Werner Dittrich; Jochen Kruip; Thorsten Schmidt; Joerg Birkenfeld
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.